VEGFA and neoplasm: Dexamethasone, a synthetic glucocorticoid, counteracts this process by acting on glucocorticoid receptors, thereby decreasing both VEGF expression by tumor cells and VEGF sensitivity of the endothelial target cells (Sareddy et al., 2013).